The HMGB1/RAGE axis induces bone pain associated with colonization of 4T1 mouse breast cancer in bone by Okui, Tatsuo et al.
Journal of Bone Oncology 26 (2021) 100330Contents lists available at ScienceDirect
Journal of Bone Oncology
journal homepage: www.elsevier .com/ locate/ jboResearch PaperThe HMGB1/RAGE axis induces bone pain associated with colonization
of 4T1 mouse breast cancer in bonehttps://doi.org/10.1016/j.jbo.2020.100330
2212-1374/ 2020 The Authors. Published by Elsevier GmbH.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Abbreviations: ALP, alkaline phosphatase; BC, breast cancer; BCABP, breast
cancer-associated bone pain; CGRP, calcitonin gene-related peptide; CM, condi-
tioned medium; CREB, cyclic AMP-responsive element-binding protein; DAMP,
damage-associated molecular pattern; DbcAMP, dibutyryl cyclic AMP; DRG, dorsal
root ganglion; ERK, extracellular signal-regulated kinase; HMGB1, high mobility
group box 1; M-CSF, macrophage colony-stimulating factor; MNOCs, multinucle-
ated osteoclast-like cells; pERK, phosphorylated ERK; pCREB, phosphorylated CREB;
RAGE, receptor for advanced glycation end products; RANKL, receptor activator of
NF-jB ligand; SN, sensory neuron; TRAP, tartrate-resistant acid phosphatase; TRL,
toll-like receptor; 4T1 mice, mice intratibially inoculated with 4T1 BC cells; 4T1/sh
control mice, mice intratibially inoculated with 4T1 BC/sh control cells; 4T1/sh
HMGB1 mice, mice intratibially inoculated with 4T1 BC/sh HMGB1 cells.
⇑ Corresponding author at: Department of Cellular and Molecular Biochemistry,
Osaka University Graduate School of Dentistry, 1-8 Yamadaoka, Suita, Osaka 565-
0871, Japan.
E-mail address: tyoneda@dent.osaka-u.ac.jp (T. Yoneda).Tatsuo Okui a,c, Masahiro Hiasa b,c, Shoji Ryumon a, Kisho Ono a, Yuki Kunisada a, Soichiro Ibaragi a,
Akira Sasaki a, G. David Roodman c,d, Fletcher A. White e, Toshiyuki Yoneda c,f,⇑
aDepartment of Oral and Maxillofacial Surgery and Biopathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan
bDepartment of Biomaterials and Bioengineerings, University of Tokushima Graduate School of Dentistry, Tokushima, Japan
cDepartment of Medicine, Hematology Oncology, Indiana University School of Medicine, Indianapolis, IN, USA
d The Rodebusch VA, Indianapolis, IN, USA
eDepartment of Anesthesia, Paul and Carole Stark Neurosciences Research Institute, Indianapolis, IN, USA
fDepartment of Cellular and Molecular Biochemistry, Osaka University Graduate School of Dentistry, Osaka, Japan
a r t i c l e i n f o a b s t r a c tArticle history:
Received 26 July 2020
Revised 6 October 2020
Accepted 6 October 2020






RAGEBone pain is a common complication of breast cancer (BC) bone metastasis and is a major cause of
increased morbidity and mortality. Although the mechanism of BC-associated bone pain (BCABP) remains
poorly understood, involvement of BC products in the pathophysiology of BCABP has been proposed.
Aggressive cancers secrete damage-associated molecular patterns (DAMPs) that bind to specific DAMP
receptors and modulate cancer microenvironment. A prototypic DAMP, high mobility group box 1
(HMGB1), which acts as a ligand for the receptor for advanced glycation end products (RAGE) and toll-
like receptors (TLRs), is increased in its expression in BC patients with poor outcomes. Here we show that
4T1 mouse BC cells colonizing bone up-regulate the expression of molecular pain markers, phosphory-
lated ERK1/2 (pERK) and pCREB, in the dorsal root ganglia (DRGs) innervating bone and induced
BCABP as evaluated by hind-paw mechanical hypersensitivity. Importantly, silencing HMGB1 in 4T1
BC cells by shRNA reduced pERK and pCREB and BCABP with decreased HMGB1 levels in bone.
Further, administration of a neutralizing antibody to HMGB1 or an antagonist for RAGE, FPS-ZM1, ame-
liorated pERK, pCREB and BCABP, while a TLR4 antagonist, TAK242, showed no effects. Consistent with
these in vivo results, co-cultures of F11 sensory neuron-like cells with 4T1 BC cells in microfluidic culture
platforms increased neurite outgrowth of F11 cells, which was blocked by HMGB1 antibody. Our results
show that HMGB1 secreted by BC cells induces BCABP via binding to RAGE of sensory neurons and sug-
gest that the HMGB1/RAGE axis may be a potential novel therapeutic target for BCABP.
 2020 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Breast cancer (BC) frequently metastasizes to bone, inducing
osteolytic metastases accompanied by severe bone pain [1].
BC-associated bone pain (BCABP) is a major cause of increased
morbidity and mortality in BC patients [2]. However, currently-
available treatments for BCABP are still unsatisfactory and
inappropriate [3]. According to the recommendation of the WHO
analgesic ladder, opioids are the mainstay of cancer pain manage-
ment and reasonably control BCABP in BC patients [4]. However,
opioid produces troublesome side-effects including cognitive dis-
turbances, sedation, constipation and respiratory depression.
Long-term opioid use causes addiction, drug abuse, osteopenia
and osteoporosis [5]. Non-steroidal anti-inflammatory drugs are
often used for BCABP but their effects are limited due to the short
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have potential adverse effects on renal, gastrointestinal, cardiovas-
cular and hematological systems [3].
Although the mechanism of BCABP remains poorly understood,
it has been proposed that the products of the cellular components
in the BC microenvironment including metastatic BC cells, stromal
cells, immune cells, adipocytes, endothelial cells, and bone cells
(osteoclasts, osteoblasts, and osteocytes) induce sensitization and
excitation of sensory neurons (SNs) that innervate bone and could
contribute to BCABP [6].
Aggressive cancer cells release damage-associated molecular
patterns (DAMPs) from the necrotic core in the tumor [7]. Secreted
DAMPs then promote the development, progression, and metasta-
sis of cancer by initiating noninfectious inflammatory responses
[8]. High mobility group box 1 (HMGB1), which is a highly con-
served ubiquitous nuclear non-histone DNA-binding protein and
a prototypic member of DAMPs [9], is passively released from
dead, dying and injured cells. However, recent reports showed that
HMGB1 is also actively secreted from cancer cells in response to
various stimuli [10]. Extracellular HMGB1 acts by binding to cell
surface receptors such as receptor for advanced glycation end
products (RAGE), toll-like receptor 2, 4 and 9 (TLR2, TLR4 and
TLR9), syndecan-1, and Mac-1, to propagate inflammatory and pain
signals [9,10]. Of note, clinical studies reported that HMGB1 levels
are increased in tumor tissue and circulating blood in BC patients
with poor outcomes [11]. Recently, HMGB1 was found to mediate
inflammatory and immune reactions in nervous systems [12] and
implicated in neuropathic and chronic pain [13], leading us to
the hypothesis that HMGB1 plays a role in BCABP. To test this
hypothesis, we established an animal model of BCABP in which
4T1 mouse BC cells were injected into the bone marrow cavity of
tibiae (hereafter these mice are designated as 4T1 mice). BCABP
was evaluated by hind-paw mechanical hypersensitivity, a
widely-used behavior assay for bone pain in rodents [14] and the
expression of phosphorylated extracellular-regulated kinase 1/2
(ERK1/2) and cyclic AMP-responsive element-binding protein
(CREB), two molecular markers of pain [15]. Using this model, we
found that HMGB1 secreted from BC induced BCABP via activation
of RAGE of SNs. We propose that blockade of the HMGB1/RAGE axis
may be an effective approach for the treatment of bone pain in
patients with advanced BC.2. Methods
All animal studies were approved by the Institutional Animal
Care and Use Committee at Indiana University School of Medicine
(Protocol #: 10553) and conducted according to the ARRIVE
guidelines.2.1. Reagents
Anti-RAGE antibody (anti-mouse, monoclonal #sc-80652) was
purchased from SantaCruz Biotechnology, (Dallas, TX) anti-TLR4
(anti-mouse, monoclonal #ab22048 anti-HMGB1 antibody (anti-
rabbit, monoclonal, ab79823), anti-CGRP antibody (anti-goat, poly-
clonal, #ab36001) and anti-peripherin antibody (anti-rabbit,
#ab4666) were purchased from Abcam (Cambridge, MA). Anti-
HMGB1 neutralizing antibody (Chicken IgY, # 326052233) and
control antibody (Chicken IgY #326058471) were purchased from
Shino test corporation (Tokyo, Japan). Anti-phospho-p44/42 MAPK
antibody (anti-rabbit, monoclonal, #4370), anti-p44/42 MAPK
antibody (anti-rabbit, monoclonal, #4695), anti-phospho CREB
(anti-rabbit, monoclonal, #9198), horseradish peroxidase (HRP)-
conjugated IgG antibody (anti-rabbit, monoclonal, #7074),
HRP-conjugated IgG antibody (anti-mouse, monoclonal, #7076),2
anti-mouse IgG (H + L), F(ab0)2 Fragment (Alexa Fluor 647 Conju-
gate) #4410, and anti-rabbit IgG (H + L), F(ab’)2 Fragment (Alexa
Fluor 488 Conjugate) #4412 were purchased from Cell Signaling
Technology (Danvers, MA).
2.2. BC cells
Mouse 4T1 BC cells were obtained from the Human Science
Resources Bank (Osaka, Japan) and cultured in DMEM (Thermo
Fisher Scientific, Waltham, MA) supplemented with 10% heat-
inactivated FBS and 1% penicillin–streptomycin in an atmosphere
of 5% CO2 at 37 C. Human BC cell lines MDA-MB-231 and MCF-7
were obtained from the American Type Culture Collection (ATCC;
Manassas, VA, USA). Cells were analyzed and authenticated by tar-
geted genomic and RNA sequencing.
2.3. SN cells of dorsal root ganglion (DRG)
Primary rat SN cells of DRGs were purchased from Lonza (R-
DRG-505, Alpharetta, GA) and cultured in primary neuron growth
medium (Lonza, CC-4461) with 2% FBS, L-glutamine, gentamycin
sulfate-amphotericin (GA-1000, Lonza, CC-4083) and neural sur-
vival factor-1 (NSF-1, Lonza, CC-4323) as per the supplier’s guide-
lines. The rat DRG/mouse neuroblastoma hybrid cell line F11 [16],
and immortalized rat DRG neuronal cells 50B11 [17], a generous
gift from Dr. Hoke (Department of Neurology, School of Medicine,
Johns Hopkins University, Baltimore, MD), were cultured in neu-
robasal medium (Gibco) supplemented with 10% FBS, 1 B27 sup-
plement (Gibco), 0.2% glucose and 0.5 mM glutamine (neuron
growth medium).
2.4. Cell proliferation
Cells were plated in six-well plates at 1  105 cells per well. The
cell number was counted after 72 h of culture with a TC20 auto-
mated cell counter (Bio-Rad, Hercules, CA).
2.5. Neurite outgrowth of SN cells
The F11 or 50B11 SN cells were plated in 48-well plates
(1.0  104/well) in the neuron growth medium for 24 h and subse-
quently cultured in the absence or presence of the conditionedmed-
ium (CM, 20% v/v) harvested from 4T1 BC cell cultures with or
without HMGB1 neutralizing antibody or control IgY antibody for
5 days. Plates were then stained with calcein-acetoxymethyl (AM)
(1 lM) for 10 min and the length of all outgrowing fluorescent neu-
rites and the number of fluorescent SN cells in plates were deter-
mined using Neuron J software under a fluorescent microscope
(Olympus IX71, Tokyo, Japan) as previously described [18]. Neurite
outgrowthof SNcellswas calculatedas lengthof all outgrowingneu-
rites/number of total SN cells and is shown as lm/SN cell in figures.
2.6. Co-culture of SNs and BC cells in microfluidic culture platform
Induction of neurite outgrowth from F11 SN cells over distances
in response to extracellular factors released from 4T1 BC cells was
evaluated in microfluidic culture platforms as described [19]. Sus-
pensions of F11 SN cells (105 cells/10 ml) was plated into the left
channels of the microfluidic culture platform (AXISTM, Millipore, Bil-
lerica, MA), and the right channels were filled with neuron growth
medium. After 12 h of culture, the medium was removed and 4T1
BC cells (106 cells/ml) were plated into the right channels and the
microfluidic culture platforms were cultured for an additional
48 h. Non-adhered cells and debris were then washed out with
PBS, and the channels labeled with calcein AM. The number of
F11 SN cells that exhibited neurite outgrowth longer than 50 lm
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using Neuron J software.
2.7. Silencing HMGB1 expression in BC cells
The 4T1 BC cells were infected with 1 mg control short hairpin
shRNA or HMGB1 shRNA using a Lenti virus particle transduction
system (sc-37983-V, SantaCruz Biotechnology, Dallas, TX). After
infection, the cells were cultured in DMEM plus 10% FBS for 5 days
in the presence of 2 mg/ml puromycin dihydrochloride for selection
of cells that stably expressed the shRNAs.
2.8. Osteoclastogenesis in mouse bone marrow cultures
Osteoclastogenesis in bone marrow macrophage cultures was
determined as we described [20]. In brief, four-week-old male
C57BL/6 mice were sacrificed by cervical dislocation and bone
marrow cells in the femurs and tibiae were harvested by flushing
out with phosphate-buffered saline using a 27 gauge needle. The
cells were then incubated in a-MEM with 30 ng/ml macrophage-
colony-stimulating factor (M-CSF) (R&D System, Minneapolis,
MN) for 24 h. Non-adherent cells were transferred to 48-well
plates (1  105 cells/well) and treated with suboptimal dose of
30 ng/ml M-CSF and 10 ng/ml receptor activator of NF-jB ligand
(RANKL) (PEPROTECH, Rocky Hill, NJ) in the absence or presence
of 4T1 CM (20%, v/v) and with or without the TLR4 antagonist
TAK-242 or RAGE antagonist FPS-ZM1. Following five days of cul-
ture, the cells were fixed and stained for tartrate-resistant acid
phosphatase (TRAP) using a TRAP/alkaline phosphatase (ALP) Stain
Kit (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan). The
number of TRAP-positive multinucleated osteoclast-like cells
(TRAP+ MNOCs) (nuclear number > 3) in each well were counted
under a microscope.
2.9. Intratibial injection of BC cells in mice
The 4T1 BC cells (1  105 cells/10 ll) were inoculated in the
bone marrow cavity of right tibiae of 4 to 6-week-old female
BALB/c mice (4T1 mice) (Harlan Laboratories, Indianapolis, IN),
under general anesthesia with ketamine (Ketaset; 90–150 mg/kg,
ip) and xylazine (AnaSed; 5–10 mg/kg, ip) as we described [21].
Sham surgery control mice were injected intratibially with PBS.
2.10. Radiological analysis of osteolytic lesions
Bone destruction in tibiae associated with 4T1 BC colonization
was assessed by radiographs. Bones were placed against films
(22  27 cm; Fuji Industrial Film FR: Fuji Photo Film Co., Tokyo)
and exposed to soft X-rays at 35 kV for 15 s with a Sofron appara-
tus (Sofron, Tokyo, Japan). The area of the radiolucent osteolytic
lesions was quantified using Lumina Vision/OL (Mitani, Tokyo,
Japan) with a microscope (IX81, Olympus, Tokyo, Japan) as we
described [22].
2.11. Evaluation of BCABP by hind-pawmechanical hypersensitivity by
von Frey test
Nociceptive behavior of 4T1 mice was evaluated by hind-paw
mechanical hypersensitivity by the von Frey test using the
Dynamic Plantar Aesthesiometer (Ugo Basile, Gemonio, VA, Italy)
(Fig. 1A, left) as we described [23]. The von Frey test has been
widely used for pain assessment in rodents [14]. This test determi-
nes a rodent sensitivity to mechanical stimuli using von Frey fila-
ment. Prior to undergoing a pain behavioral test, mice were
acclimatized to the environment and facilities for 5–7 days. The
hind-paws of animals standing on an elevated mesh platform3
(Fig. 1A left) are poked by a single von Frey filament with auto-
mated increasing force (Fig. 1A, right), so that the force by which
animals are induced to show hind-paw withdrawal can be quanti-
tatively estimated. The force is shown as paw withdrawal thresh-
old (g) in figures. Rodents with pain exhibit paw withdrawal
with lighter force than those without pain. The test was performed
prior to 4T1 BC cell injection to determine the baseline pain behav-
iors of mice, and every 3–4 days following intratibial injection of
4T1 BC cells until the end of the experiment. Intratibial injection
of 4T1 BC cells and von Frey test were performed by researchers
who were blinded to the experiments.
2.12. Harvest of DRGs, tibiae, sera and bone marrow fluids
Whole blood was collected by cardiac puncture under general
anesthesia. Mice were then sacrificed by cervical dislocation and
lumbar DRGs (L3–L5) and tibiae were harvested. The lumbar DRGs
were immediately homogenized in RIPA lysis buffer with 1 mM
phenylmethylsulfonyl fluoride (PMSF) and phosphatase inhibitors
(Na3VO4 and NaF). The lysates were centrifuged at 15,000g for
5 min at 4 C, and the supernatants collected. Some DRGs were
fixed in 10% neutral-buffered formalin and embedded in paraffin
for subsequent histological analyses.
For collection of bone marrow fluids from tibiae, muscles and
connective tissues were removed, both ends of tibiae were cut,
and whole bone marrow was flushed out with 100 ml PBS, the tubes
centrifuged, and the supernatants collected.
2.13. Immunoblotting for phosphorylated extracellular signal-
regulated kinase (pERK) and cyclic AMP responsive element-binding
protein (pCREB)
DRG lysates were mixed with 4 Laemmli sample buffer (Bio-
Rad Laboratories, Hercules, CA), heated at 95 C for 5 min, elec-
trophoresed in 4–12% SDS-PAGE gels. Proteins were transferred
onto PVDF membranes (Bio-Rad), incubated with primary and sec-
ondary antibodies according to the Trans-Blot turbo transfer sys-
tem protocol (Bio-Rad) to detect secondary antibody binding.
Antibodies against HMGB1 (1:1000), pERK (1:1000), ERK
(1:1000), pCREB (1:1000), and CREB (1:1000) were used as primary
and HRP-conjugated anti-rabbit antibody (1:2000) and HRP-
conjugated anti-mouse antibody (1:2000) as secondary. Immuno-
blots were analyzed by Image J software.
2.14. Histologic analysis of bone
Tibiae were harvested, fixed in 10% neutral buffered formalin
for 48 h, decalcified in 10% EDTA for two weeks, embedded in
paraffin, sectioned and stained with hematoxylin and eosin (HE).
2.15. TRAP staining of tibiae of 4T1 mice
Bone sections were stained for TRAP using a TRAP & ALP
double-stain Kit (Takara Bio, Mountain View, CA) and analyzed
for osteoclastic bone destruction using Magnafire 4.1 software
(Optronics, Goshen, IN) under a microscope (IX81, Olympus).
TRAP+OCs were counted at tumor-bone interface at endocortical
bone using three levels of sections for each sample according to
the methods previously reported [24]. Data are expressed as the
number of osteoclasts/bone surface (mm) (No. OC/BS/mm).
2.16. Immunofluorescence
Immunofluorescence analysis was used to determine the
expressions of peripherin and RAGE and TLR4 in DRGs from each
group of mice. The specimens were incubated with 3% bovine
Fig. 1. A mouse model of BCABP. (A) Assessment for hind-paw mechanical hypersensitivity in tibiae of mice by von Frey test. Picture of a mouse withdrawing left hind-leg
following poking with von Frey filament (left). The dynamic plantar aesthesiometer with von Frey filament that pokes mouse hind-paw with automated increasing force
(right). Mice with pain exhibit hind-paw withdrawal with lighter force than those without pain. (B) Radiograph of osteolytic lesions in tibiae associated with 4T1 BC
colonization at day 15 of intratibial cell inoculation (1  105 cells/10 ll) in sham (left) and 4T1 mouse (right). Multiple osteolytic lesions are seen in tibiae of 4T1 mouse
(right). Scale bar 1 mm. (C) Progression of hind-paw mechanical hypersensitivity in tibiae of 4T1 mice. The force of the filament by which mice withdrew their hind-paw is
shown on Y-axis as paw withdrawal thresholds (g) in figure. Mice with BCABP in tibiae show decreased paw withdrawal threshold in parallel with the extent of BCABP. For
example, sham mice withdrew their hind-leg by the force of 10.78 ± 1.08 g (Mean ± SD), while 4T1 mice by 5.5 ± 1.45 g (Mean ± SD) at day 9. Decreased paw withdrawal
threshold in all group of mice at day 2 is due to surgical trauma. To evaluate therapeutic effects, the neutralizing antibody to HMGB1 (2 mg/kg/mouse, ip, once a day) or
control IgY antibody was given at day 13, 14 and 15 (arrows) when 4T1 mice demonstrated considerable hind-paw mechanical hypersensitivity with clearly discernible
osteolysis in tibiae associated with 4T1 BC colonization on radiographs. The HMGB1, but not IgY control, antibody significantly reduced hind-paw mechanical
hypersensitivity in tibiae of 4T1 mice. Mice withdrew their hind-leg by the force of 4.85 ± 0.22 g (Mean ± SD) before administration of the HMGB1 antibody and by
7.07 ± 0.26 g (Mean ± SD) after administration of the HMGB1 antibody. Data are shown as mean ± SD (n = 8). * Significantly different from shammice (p < 0.05). # Significantly
different from 4T1 and 4T1 + IgY mice (p < 0.05). (D) Expression of a molecular pain marker pERK in DRGs harvested from sham and 4T1 BC mice treated with or without the
HMGB1 antibody. After sacrifice at day 17, DRGs were harvested, immediately lysed and subjected to Western analysis. Expression of pERK was increased in 4T1 mice with
BCABP. Administration of the HMGB1 antibody reduced pERK expression in DRGs of 4T1 mice. ERK1/2 expression was not changed.
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solution, and then with mouse anti-RAGE (1:100) and mouse
anti-TLR4 antibody (1:100) and rabbit anti-peripherin (1:100) anti-
body overnight at 4 C as primary antibodies, followed by Alexa
Fluor 647 anti-mouse IgG (1:1000) and Alexa Fluor 488 anti-
rabbit IgG (1:1000) as secondary antibodies.4
2.17. Tissue microarrays
HMGB1 expression in human BCs and normal breast tissue was
determined using tissue microarrays (#BRM971; US Biomax, Rock-
ville, MD). The antigen was activated by cooking in a citric acid
solution. For immunohistochemical analysis, specimens were
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MA) overnight at 4 C, followed by the treatment with
streptoavidin-biotin complex (1:100, EnVision System labeled
polymer, HRP; Dako, Carpinteria, CA) for 60 min, and visualized
with the use of a DAB substrate-chromogen solution (Dako
Cytomation Liquid DAB Substrate Chromogen System). Quantifica-
tion was performed using a BZ-X800 analyzer hybrid cell count
system (Keyence, Osaka, Japan), and the relative integrated density
was calculated as number of HMGB1-positive BC cells/specimen
or/number of total BC cells  100.
2.18. Determination of HMGB1 levels
HMGB1 levels in the circulating blood and bone marrow fluids
of tibiae were determined by ELISA (Shino test, Tokyo) according
to the manufacturer’s instructions.
2.19. Statistical analysis
Data were analyzed using an unpaired Student’s t-test for com-
parisons of two groups and by performing a two-way analysis of
variance (ANOVA) and a post hoc Tukey’s test for the analysis of
multiple group comparisons, using SPSS statistical software, ver.
10. Results are expressed as the mean ± standard deviation (SD).
Probability (p) values <0.05 were considered significant.3. Results
3.1. Mouse model of BCABP
We first characterized 4T1 mice to evaluate if the model is suit-
able for our study. Mouse 4T1 BC cells injected into the marrow
cavity of tibiae showed aggressive growth with extensive oste-
olytic lesions in 4T1 mice (Fig. 1B, right). The 4T1 mice exhibited
time-dependent progressive hind-paw mechanical hypersensitiv-
ity (Fig. 1C). [At day 9, sham control and 4T1 mice withdrew their
hind-paw by 10.78 ± 1.08 g (Mean ± SD) and 5.5 ± 1.45 g
(Mean ± SD) threshold in von Frey test, respectively. These results
suggest that 4T1 mice had BCABP. In addition, DRGs harvested
from these 4T1 mice showed increased expression of pERK1/2
(Fig. 1D), which is a molecular pain marker [15]. These results indi-
cate that 4T1 mice represent an animal model that allows us to
perform quantitative and objective analysis of BCABP.
3.2. Role of HMGB1 in BCABP in 4T1 mice
To determine the role of HMGB1 in BCABP, we next examined
the effects of administering a neutralizing antibody to HMGB1 on
BCABP in 4T1 mice. Previous studies reported that this neutralizing
antibody reduced mortality in mice with pneumococcal meningitis
[25] and prevented oxaliplatin-induced peripheral neuropathy in
mice [26]. To determine the therapeutic effects, the HMGB1 anti-
body was administered (2 mg/kg/mouse, ip, once a day) to 4T1
mice at day 13, 14, and 15 when 4T1 mice demonstrated consider-
able hind-paw mechanical hypersensitivity with clearly dis-
cernible osteolysis in tibiae on radiographs. In preliminary
experiments, we found that one single injection of the HMGB1
antibody significantly reduced BCABP in 4T1 mice. Therefore, the
antibody was scheduled to be administered three consecutive days
to ensure the effects on BCABP. Further, since a previous study
reported that repeated administrations of the anti-HMGB1 neutral-
izing antibody for long period of time inhibit osteoclastic bone
resorption [27], which substantially contributes to the induction
of BCABP [2,28], we attempted to limit the dose of the antibody
as small as possible to minimize the effects of the antibody on bone5
resorption to evaluate the role of HMGB1 per se in BCABP unasso-
ciated with bone resorption. We found that the antibody signifi-
cantly reduced hind-paw mechanical hypersensitivity. Mice
withdrew their hind-paw by the force of 4.85 ± 0.22 g
(Mean ± SD) before administration of the HMGB1 antibody and
by 7.07 ± 0.26 g (Mean ± SD) after administration of the HMGB1
antibody (Fig. 1C), demonstrating that the HMGB1 antibody
relieved BCABP in 4T1 mice. The antibody also decreased pERK1/2
expression in DRGs harvested from 4T1 mice (Fig. 1D). Control IgY
antibody showed no effects on BCABP (Fig. 1C). These results sug-
gest that HMGB1 plays a critical role in the induction of BCABP and
SN activation in 4T1 mice.
We then examined if 4T1 BC express HMGB1 by Western anal-
ysis and verified that 4T1 BC, as well as MDA-MB-231 and MCF-7
human BC cells, express HMGB1 (Fig. 2A). Further, ELISA showed
that HMGB1 levels in the bone marrow of tibiae injected with
4T1 BC cells were elevated compared to sham surgery mice
(Fig. 2B), demonstrating that 4T1 BC cells secrete HMGB1 in vivo
as well. Of note, serum levels of HMGB1 were not significantly dif-
ferent between sham surgery mice and 4T1 mice (Fig. 2C), suggest-
ing that HMGB1 secretion by 4T1 BC cells in tibiae is not sufficient
enough to elevate circulating levels of HMGB1.
To further determine the role of HMGB1 produced by 4T1 BC in
the induction of BCABP, 4T1 BC cells in which HMGB1 was silenced
by knockdown by sh HMGB1 (4T1/sh HMGB1 cells) were generated
and intratibially inoculated in mice (4T1/sh HMGB1 mice). Knock-
down of HMGB1 in 4T1/sh HMGB1 cells was validated by western
analysis (Fig. 2D). Silencing HMGB1 did not change cell prolifera-
tion of 4T1 BC cells in monolayer culture (data not shown). HMGB1
levels in the bone marrow of tibiae, however, were significantly
decreased in 4T1/sh HMGB1 mice compared to 4T1 mice and mice
intratibially injected with 4T1/sh control cells (4T1/sh control
mice) (Fig. 2B), whereas serum HMGB1 levels were not signifi-
cantly changed in 4T1/sh HMGB1 mice compared to 4T1 and
4T1/sh control mice (Fig. 2C). Importantly, the expression of
molecular pain markers, pERK1/2 and pCREB, in DRGs (Fig. 2E)
was decreased in 4T1/sh HMGB1 mice compared to 4T1 and 4T1/
sh control mice. More importantly, BCABP evaluated by hind-paw
mechanical hypersensitivity was significantly reduced in 4T1/sh
HMGB1 mice compared to 4T1 and 4T1/sh control mice (Fig. 2F),
i.e. 4T1 mice withdrew their hind-leg by the force of 3.84 ± 0.84 g
(Mean ± SD), while 4T1/sh HMGB1 mice by 7.26 ± 0.43 g
(Mean ± SD) at day 10. Consistent with these results, immunofluo-
rochemical examination showed that axogenesis of peripherin+
SNs was increased in the bone marrow of tibiae of 4T1 and 4T1/
sh control mice (Fig. 2G). In contrast, the axogenesis of peripherin+
SNs was decreased in 4T1/sh HMGB1 mice. Quantitative determi-
nation revealed that peripherin+ neurons in tibiae of 4T1 and
4T1/sh control mice are 1.506 ± 0.51% (Mean ± SD) and
1.497 ± 0.52% (Mean ± SD), respectively and 0.496 ± 0.34%
(Mean ± SD) in 4T1/sh HMGB1 mice, validating the histological
results (Fig. 2H). These results suggest that HMGB1 locally secreted
by 4T1 BC cells in the bone marrow of tibiae is responsible for
increased axogenesis of SNs in tibiae and induction of BCABP in a
paracrine manner.
3.3. Role of HMGB1 receptors, receptor activation glycation products
(RAGE) and toll-like receptor 4 (TLR4) in BCABP
To further determine the role of HMGB1 in BCABP, we next
examined if SNs in bone express two of the major HMGB1 recep-
tors, RAGE and TLR4. HMGB1 is known to act primarily by binding
and activating RAGE and TLR4 [9,10]. Immunofluorochemical
examination of tibiae showed that RAGE and TLR4 were expressed
on peripherin+ SNs innervating bone (Fig. 3A). We then examined
the effects of TAK-242, an antagonist for TLR4 [29], and FPS-ZM1,
Fig. 2. Role of HMGB1 produced by 4T1 BC in BCABP. (A) Expression of HMGB1 in mouse 4T1 BC and human BC MDA-MB-231 and MCF-7 cells in culture. Whole cell lysates
were subjected to Western analysis. HMGB1 levels in the bone marrow of tibiae by ELISA. Bone marrow fluids were collected as described in Methods from sham, 4T1, 4T1/sh
control and 4T1/sh HMGB1 mice. (B) HMGB1 levels were increased in the bone marrow of tibiae of 4T1 and 4T1/sh control mice, while significantly decreased in the bone
marrow of tibiae of 4T1/sh HMGB1mice. Data are shown as mean ± SD (n = 8). * Significantly different from shammice (p < 0.05). # Significantly different from 4T1 and 4T1/sh
control mice (p < 0.05). (C) HMGB1 levels in circulating serum determined by ELISA. Sera were collected as described in Methods from sham, 4T1, 4T1/sh control and 4T1/sh
HMGB1mice. There was no difference in serum levels of HMGB1 among 4T1, 4T1/sh control and 4T1/sh HMGB1mice. Data are shown asmean ± SD (n = 8). ns: not significantly
different from sham. (D) Knockdown of HMGB1 by shRNA in 4T1 BC cells. HMGB1 expression was evaluated byWestern analysis in parental 4T1 BC, 4T1/sh control and 4T1/sh
HMGB1 cells. HMGB1 expression is successfully reduced in 4T1/sh HMGB1 cells. (E) Expression of molecular pain markers pERK1/2 and pCREB in DRGs of sham, 4T1, 4T1/sh
control and 4T1/sh HMGB1 mice. DRGs were harvested after sacrifice at day 15, immediately lysed and subjected to Western analysis. Expression of pERK1/2 and pCREB was
increased in DRGs of 4T1 and 4T1/sh control mice compared to shammice and decreased in DRGs of 4T1/sh HMGB1mice compared to 4T1 and 4T1/sh control mice. Expression
of ERK1/2 and CREB was not changed. (F) Progression of hind-paw mechanical hypersensitivity in tibiae of intact, sham, 4T1, 4T1/sh control and 4T1/sh HMGB1 mice. Sham
mice showed hind-paw mechanical hypersensitivity until surgical trauma healed. 4T1 mice withdrew their hind-leg by the force of 3.84 ± 0.84 g (Mean ± SD), while 4T1/sh
HMGB1mice by 7.26 ± 0.43 g (Mean ± SD) at day 10. Data are shown as mean ± SD (n = 8). * Significantly different from intact and shammice (p < 0.05). # Significantly different
from 4T1 and 4T1/sh control mice (p < 0.05). (G) Axogenesis of peripherin+ SNs in the bone marrow of tibiae by immunofluorescent staining. Tibiae were harvested from sham,
4T1, 4T1/sh control and 4T1/sh HMGB1 mice after sacrifice at day 15, fixed, decalcified and processed for subsequent histological analyses. Bone sections were incubated with
rabbit anti-peripherin (1:100) antibody overnight at 4 C as primary antibodies, and then with donkey anti-rabbit IgG (1:100) as secondary antibody, followed by Alexa Fluor
488 anti-rabbit IgG (1:1000). Peripherin is a marker for SN. White asterisks in the figures indicate cortical bone. Peripherin+ SNs were increased in the bone marrow of tibiae of
4T1 and 4T1/sh control mice compared to sham mice and decreased in the bone marrow of tibiae of 4T1/sh HMGB1 mice compared to 4T1 and 4T1/sh control mice. Scale bar
250 mm. (H) Quantitative evaluation of peripherin+ SNs in the bone marrow of tibiae seen in Fig. 2G. Peripherin+ fluorescent area and whole bone marrow area in histological
sections were quantified under a fluorescentmicroscope using Neuron J software. Peripherin+ SNs (%) on Y-axis in the figure was calculated as peripherin+ fluorescent area/total
bone marrow area 100. Peripherin+ SNs were increased in 4T1 mice, which was decreased by the treatment with HMGB1 antibody. Data are shown as mean ± SD (n = 8).
* Significantly different from sham mice (p < 0.05). # Significantly different from 4T1 and 4T1/sh control mice (p < 0.05).
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to determine which receptor signal pathway is predominantly acti-
vated by HMGB1 to induce BCABP. The 4T1 mice showing BCABP
were given a single intra-plantar injection of either TAK-242 or
FPS-ZM1 at day 14 and evaluated for changes in BCABP. FPS-ZM1
reduced hind-pawmechanical hypersensitivity as early as 3 h after
injection from 3.56 ± 0.39 g (Mean ± SD) to 5.18 ± 0.43 g
(Mean ± SD), which lasted until 12 h (untreated vs FPS-ZM1 =
3.27 ± 0.19 g vs 5.22 ± 0.21 g) (Mean ± SD) and disappeared after
18 h (Fig. 3B). HMGB1 antibody also reduced hind-paw mechanical
hypersensitivity 12 h after injection (untreated vs HMGB1
antibody = 3.27 ± 0.19 g vs 6.92 ± 0.65 g) (Mean ± SD), which lasted
until 24 h (untreated vs HMGB1 antibody = 3.33 ± 0.15 g vs 6.38
± 0.64 g) (Mean ± SD). Overall, HMGB1 antibody seemed to be
more effective than FPS-ZM1 at relieving BCABP under this exper-
imental conditions. In contrast, TAK-242 given on this experimen-
tal protocol showed little effects on BCABP. Further, FPS-ZM1 and
HMGB1 antibody decreased pERK1/2 and pCREB in DRGs of 4T1
mice (Fig. 3C), while TAK-242 had no effects. These results suggest
that HMGB1/RAGE axis is more predominant in the regulation of
SN activity and induction of BCABP than HMGB1/TLR4. Role of
TLR4 in BCABP needs further investigation. In addition, it should
be noted that in this experiment, HMGB1 antibody and antagonists
were given by only one single injection and BCABP was evaluated
within 24 h. Under these circumstances, it is unlikely that 4T1
tumor burden in bone is changed. Thus, our results suggest that
HMGB1 directly can regulate SN activity and BCABP independent
of tumor burden.
3.4. Effects of HMGB1 secreted from 4T1 BC cells on DRG SN cells
in vitro
To further determine the effects of HMGB1 produced by 4T1 BC
on DRG SNs, we examined neurite outgrowth of F11 SN cells co-
cultured with 4T1 BC cells in the absence or presence of the neu-
tralizing antibody to HMGB1 in the microfluidic culture platforms.
Few F11 SN cells cultured in the medium showed neurite out-
growth (Fig. 4A, left). In contrast, many F11 SN cells exhibited neu-
rite outgrowth toward 4T1 BC cells in the co-culture (Fig. 4A, right).
In agreement with these microscopic observations, the number of
F11 SN cells with outgrowing neurites longer than 50 lm was con-
siderably increased in the co-culture with 4T1 BC cells (Fig. 4B).
Importantly, the neutralizing antibody to HMGB1 significantly
decreased the number of F11 SN cells with neurite outgrowth by
more than 50% (Fig. 4B). Control IgY antibody showed no effects.
We next determined the effects of the conditioned medium
(CM) harvested from 4T1 BC cultures on neurite outgrowth of SN
cells. Microscopic observation showed that 4T1 BC CM (20%, v/v)
significantly increased F11 SN cells with outgrowing neurites
(Fig. 4C). Assessment for the length of neurites extending from
F11 SN cells revealed that F11 SN cells treated with 4T1 CM signif-
icantly have longer outgrowing neurites (Fig. 4D). These effects of
4T1 CM were blocked by the HMGB1 antibody by 60% (Fig. 4D).
Dibutyryl cyclic AMP (DbcAMP, 1 mM), which served as a positive
control, also increased neurite length of F11 SN cells. These results
are in agreement with those obtained in 4T1 mice and suggest that
4T1 BC cells increase axogenesis of DRG SNs via secretion of
HMGB1.
3.5. Role of HMGB1 in the progression of osteolysis associated with 4T1
BC colonization in bone
We next determined the role of HMGB1 in 4T1 BC colonization
in bone. Radiological examination of osteolytic lesions to monitor
4T1 BC colonization in bone revealed that there are multiple oste-
olytic lesions in tibiae of 4T1 mice (Fig. 1B) and 4T1/sh control7
mice (Fig. 5A) and quantitative assessment for the area of these
osteolytic lesions validated the radiographic results (Fig. 5B). In
contrast, the area of osteolytic lesions was significantly decreased
in 4T1/sh HMGB1 mice. Further, histological analysis demon-
strated that the number of TRAP+ OCs at tumor-bone interface at
endocortical bone was increased (Fig. 5C). The number of TRAP+
OCs per mm bone surface in tibiae was increased from 3.0 ± 1.0
(Mean ± SD) in sham mice to 65.67 ± 10.02 (Mean ± SD) in 4T1
mice and significantly decreased in tibiae of 4T1/sh HMGB1 mice
to 42 ± 9.0 (Mean ± SD) (Fig. 5D). These results suggest that HMGB1
produced in 4T1 BC promoted osteoclastogenesis, leading to the
development of bone destruction associated with 4T1 BC
colonization.
In support of this notion, the CM (20%, v/v) harvested from 4T1
BC cultures increased the number of TRAP+ MNOCs in bone mar-
row macrophage cultures (Fig. 5E). It should be noted that control
and experimental groups were all treated with a suboptimal dose
of M-CSF (30 ng/ml) and RANKL (10 ng/ml) in this experiment.
To determine if increased osteoclastogenesis is due to HMGB1
secreted by 4T1 BC cells, the bone marrow macrophage cultures
were treated with the CM of 4T1 BC in the absence or presence
of increasing concentrations (10, 20 and 50 nM) of the RAGE antag-
onist FPS-ZM1 [31] or the TLR4 antagonist TAK-242 [29]. The
experimental results showed that FPS-ZM1 dose-dependently
and TAK-242 at 50 nM decreased 4T1 CM-increased osteoclastoge-
nesis (Fig. 5F). These results collectively suggest that HMGB1 pro-
duced in 4T1 BC cells regulates the development and progression
of osteoclastic bone destruction associated with 4T1 colonization
in tibiae.3.6. HMGB1 expression in human BCs
The results obtained in 4T1 mice led us to determine the pattern
of HMGB1 expression in human BCs. Immunohistochemical analy-
sis using human BC and normal breast tissue microarray showed
that HMGB1+ cells are significantly increased in human BCs com-
pared to human normal breast tissues (Fig. 6A and 6B). These
results suggest that HMGB1 contributes to BC tumorigenesis as
previously reported [32].
HMGB1, which is a nuclear protein, is translocated to the cyto-
plasm prior to release into the extracellular space to exert its bio-
logical effects [10]. We therefore determined cytoplasmic and
nuclear expression of HMGB1 in human BCs by immunohisto-
chemistry (Fig. 6C). Of note, the percent of cells that express HMGB
in the cytoplasm/cells that express HMGB1 in the cytoplasm and
nucleus was significantly greater in BCs (60.3 ± 3.9%, Mean ± SD,
n = 6) than normal breast tissues (29.8 ± 6.3%, Mean ± SD,
n = 51) (Fig. 6D, right), while the percent of cells that express
HMGB in the nucleus/cells that express HMGB1 in the cytoplasm
and nucleus was equivalent between BCs and normal breast tissue
(Fig. 6D, left). Taken together, these results suggest that transloca-
tion of HMGB1 from the nucleus to the cytoplasm may be critical
for BC to induce BCABP.4. Discussion
In this study we showed that HMGB1 secreted from
intratibially-injected 4T1 BC cells induces BCABP in mice. HMGB1,
which is a prototypic member of DAMPs, is secreted by a wide
range of cancers and functions like a cytokine, creating an inflam-
matory cancer microenvironment [7]. Recent studies suggest that
HMGB1 has both tumor-promoting and -suppressing effects during
cancer development and treatment, acting as a double-edged
sword [10]. In general, secreted HMGB1 is oncogenic by promoting
proliferation, inflammation, energy metabolism, and angiogenesis
Fig. 3. Role of RAGE and TLR4 in BCABP. (A) Immunofluorochemical analysis of RAGE and TLR4 expression on peripherin+ SNs innervating bone. Bone sections were incubated
with rabbit anti-peripherin (1:100), mouse anti-RAGE (1:100) and mouse anti-TLR4 (1:100) antibody at 4 C overnight as primary antibodies, followed by Alexa Fluor 488 anti-
rabbit IgG (1:1000) and Alexa Fluor 647 anti-mouse IgG (1:1000) as secondary antibodies. Both RAGE and TLR4 were expressed on peripherin+ SNs innervating bone. White
asterisks in the figures indicate cortical bone. Scale bar 100 mm. (B) Effects of pharmacological antagonist of RAGE and TLR4 on the progression of BCABP in 4T1 mice. One
single intra-plantar injection of the RAGE antagonist, FPS-ZM1 (10 mg/kg/mouse), the TLR4 antagonist, TAK-242 (2 mg/kg/mouse), or the neutralizing antibody to HMGB1
(2 mg/kg/mouse) was given to 4T1 mice with BCABP at day 14 (arrow), and changes in hind-paw mechanical hypersensitivity of 4T1 mice were monitored by von Frey test 3,
6, 12, 18 and 24 h after antagonist and HMGB1 antibody injection. FPS-ZM1 reduced hind-paw mechanical hypersensitivity as early as 3 h after administration from
3.56 ± 0.39 g to 5.18 ± 0.43 g (Mean ± SD), which lasted until 12 h (untreated vs FPS-ZM1 = 3.27 ± 0.19 g vs 5.22 ± 0.21 g) (Mean ± SD) and disappeared after 18 h. HMGB1
antibody also reduced hind-paw mechanical hypersensitivity 12 h after injection (untreated vs HMGB1 antibody = 3.27 ± 0.19 g vs 6.92 ± 0.65 g) (Mean ± SD), which lasted
until 24 h (untreated vs HMGB1 Antibody = 3.33 ± 0.15 g vs 6.38 ± 0.64 g) (Mean ± SD). Overall HMGB1 antibody appeared more effective than FPS-ZM1 at relieving BCABP
under this experimental conditions. TAK-242 given on this experimental protocol showed no effects on BCABP. Data are shown as mean ± SD (n = 8 for each group).
* Significantly different from 4T1 mice (p < 0.01). # Significantly different from 4T1 mice (p < 0.05). (C) Role of RAGE and TLR4 in the activation of SNs in DRGs of 4T1 mice.
DRGs were harvested from 4T1 mice after 12 h treatment with vehicle, FPS-ZM1, TAK-242 and HMGB1 antibody, immediately lysed, and subjected to Western analysis.
FPS-ZM1 and HMGB1 antibody decreased pERK1/2 and pCREB in DRGs of 4T1 mice, while TAK-242 had no effects.
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Fig. 4. Effects of HMGB1 secreted from4T1 BC cells on neurite outgrowth of DRG SN cells. (A) Effects of co-culture with 4T1 BC cells on neurite outgrowth of F11 SN cells in
microfluidic culture platforms. F11 SN cells (105 cells, left chambers) were co-cultured with 4T1 BC cells (106 cells, right chambers) for 48 h in the absence or presence of the
HMGB1 neutralizing antibody (50 lg/ml) or control IgY antibody. The chambers were then labeled with calcein AM (1 lM) for 10 min and F11 SN cells with extended neurites
were observed under a fluorescent microscope. The number of F11 SN cells exhibiting extended neurite was increased in the co-cultures with 4T1 BC cells. Scale bar 150 mm.
(B) Quantitative evaluation of neurite outgrowth in F11 SN cells in microfluidic culture platforms seen in Fig. 4A. F11 SN cells with extended neurite longer than 50 lm were
counted under a fluorescent microscope using Neuron J software and are shown on Y-axis in the figure. The number of F11 SN cells with extended neurite is significantly
increased in the co-cultures with 4T1 BC cells, and HMGB1 antibody significantly decreased the number. Data are shown as mean ± SD (n = 4). * Significantly different from
medium control (p < 0.05). # Significantly different from 4T1 or 4T1 + IgY (p < 0.05). (C) Effects of CM harvested from 4T1 BC cell cultures on neurite outgrowth of F11 SN cells.
F11 SN cells (104 cells/24-well plates) were treated with 4T1 BC cell CM (20%, v/v) in the neuron growth medium in the absence or presence of the neutralizing antibody to
HMGB1 or control IgY antibody for 5 days. The plates were then stained with calcein AM (1 lM) for 10 min and observed under a fluorescent microscope. DbcAMP (1 mM) is a
positive control. Scale bar 20 mm. (D) Quantitative evaluation of the effects of CM harvested from 4T1 BC cell cultures on neurite outgrowth of F11 SN cells. The length of all
fluorescent neurites outgrowing from the cell body of F11 SN cells, and the number of all fluorescent cell body of F11 SN cells in plates were determined using Neuron J
software under a fluorescent microscope. Neurite length (lm/cell) on Y-axis of the figure was calculated as, total length of all outgrowing neurites/number of total cell body of
F11 SN cells. Neurite length of F11 SN cell expressed on Y-axis as lm per cell was increased to 123.73 ± 6.67 lm (Mean ± SD) by treatment with 4T1 CM, which is decreased to
37.61 ± 13.78 lm (Mean ± SD) by HMGB1 antibody. Data are shown as mean ± SD (n = 4). * Significantly different from medium control (p < 0.05). # Significantly different
from 4T1 and 4T1 + IgY control antibody (p < 0.05).
T. Okui, M. Hiasa, S. Ryumon et al. Journal of Bone Oncology 26 (2021) 100330and inhibiting host anticancer immunity. In contrast, intracellular
HMGB1 has anti-tumor actions by stimulating the immunogenic
cell death of cancer cells and stimulates anti-tumor immunity9
responses during chemo- or radio-therapy. Our results suggested
that HMGB1 secreted from 4T1 BC cells is cancer-assisting by
inducing BCABP, and increasing osteolytic lesions associated with
Fig. 5. Effects of HMGB1 on osteoclastic bone destruction associated with 4T1 BC colonization in tibiae. (A) Osteolytic lesions in tibiae of mice inoculated with 4T1/sh control
(left) and 4T1/sh HMGB1 cells (right). Radiographs were taken at day 15 after intratibial cell inoculation (1  105 cells/10 ll). Scale bar 1 mm. (B) Quantitative evaluation of
osteolytic lesions in tibiae of mice inoculated with 4T1/sh control and 4T1/sh HMGB1 cells seen in Fig. 4A. The area of osteoclastic bone destruction in tibiae was determined
on radiographs using Image J. Osteolytic area (ratio) on Y-axis in the figure represents, area of 4T1/sh control or 4T1/sh HMGB1/area of 4T1 in which area of 4T1 is designated
as 1. The area of osteolytic lesions associated with 4T1/sh HMGB1 cells were significantly smaller than those of 4T1 and 4T1/sh control. Data are shown as mean ± SD (n = 8).
* Significantly different from sham control and 4T1/sh control mice (p < 0.05). (C) Histological pictures of the osteolytic lesions stained with TRAP. TRAP+OCs at tumor-bone
interface at endocortical bone are stained in red. Scale bar 50 mm. (D) Quantitative analysis of the number of TRAP+ OCs formed in Fig. 4C. The number of OCs present at
tumor-bone interface at endocortical bone was determined in three levels of histological sections for each sample under a microscope as described previously [24] and is
shown on Y-axis as No OC/Bone Surface (BS)/mm in the figure. The number of TRAP+OCs in osteolytic lesions associated with 4T1/sh HMGB1 cells was significantly less than
that of 4T1 and 4T1/sh control. Data are shown as mean ± SD (n = 4). * Significantly different from sham mice (p < 0.05). # Significantly different from 4T1 mice and 4T1/sh
control mice (p < 0.05). (E) Effects of 4T1 BC CM, FPS-ZM1 (RAGE antagonist) and TAK-242 (TLR4 antagonist) on TRAP+MNOC formation. Bone marrow macrophages (1  105
cells/48-well) were cultured with or without 4T1 BC CM (20%, v/v) and in the absence or presence of FPS-ZM1 (20 nM) and TAK-242 (50 nM) with supplementation of
suboptimal dose of M-CSF (30 ng/ml) and RANKL (10 ng/ml) for 5 days. Wells were then stained for TRAP. 4T1 BC CM increased TRAP+MNOC formation, which was decreased
by treatment with FPS-ZM1 and TAK-242. (F) Quantitative analysis of TRAP+MNOC formation in bone marrowmacrophage cultures seen in Fig. 4E. Cultures were treated with
increasing doses (10, 20 and 50 nM) of FPS-ZM1 and TAK-242 for 5 days. The number of TRAP+MNOCs was counted under a microscope. FPS-ZM1 significantly decreased
TRAP+MNOC formation in a dose-dependent manner, while TAK-242 significantly decreased it only at 50 nM. Data are shown as mean ± SD (n = 4). * Significantly different
from control (p < 0.01).# Significantly different from 4T1 CM (p < 0.05). (For interpretation of the references to colour in this figure legend, the reader is referred to the web
version of this article.)
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Fig. 6. Expression of HMGB1 in BCs using human tissue microarray. (A) Immunohistochemistry of HMGB1 expression in human normal breast tissue (top) and BC (bottom).
Specimens were incubated with anti-HMGB1 antibody (1:100) overnight at 4 C, followed by the treatment with streptoavidin-biotin complex (1:100) for 60 min, and
visualized with the use of a DAB substrate-chromogen solution. HMGB1-positive cells are stained in brown. Scale bar 50 mm. (B) Number of HMGB1-positive cells in human
normal breast tissue (n = 6) and BC (n = 51). HMGB1+ cells on specimens were counted using a BZ-X800 analyzer hybrid cell count system, and the relative integrated density
was calculated as number of HMGB1+ cells/specimen as shown on Y-axis in the figure. Data are shown as mean ± SD. * Significantly different from normal breast tissue
(p < 0.001). (C) BC cell with HMGB1-negative in nucleus and -positive in cytoplasm (top), HMGB1-positive in nucleus and -negative in cytoplasm (middle), and HMGB1-
negative in nucleus and -negative in cytoplasm (bottom). (D) Expression of HMGB1 in nucleus (left) and cytoplasm (right) in normal breast tissues (n = 6) and BC (n = 51).
Cells expressing HMGB1 in nucleus and cytoplasm in normal breast tissues and BC were counted. Y-axis in the figure indicates as, the percent of cells that express HMGB in
the nucleus/cells that express HMGB1 in the cytoplasm and nucleus 100 (left), and the percent of cells that express HMGB in the cytoplasm/cells that express HMGB1 in the
cytoplasm and nucleus 100 (right). The percent of cells expressing HMGB in the cytoplasm was significantly greater in BCs than normal breast tissues (Fig. 6D, right), while
the percent of cells expressing HMGB in the nucleus was not different between BCs and normal breast tissue (Fig. 6D, left). Data are mean ± SD. * Significantly different from
normal breast tissue (p < 0.001).
T. Okui, M. Hiasa, S. Ryumon et al. Journal of Bone Oncology 26 (2021) 1003304T1 BC colonization in bone. Importantly, we showed that the neu-
tralizing antibody to HMGB1 significantly decreased these actions
of HMGB1. These results suggest that blocking the cytokine-like
actions of secreted HMGB1 may be a therapeutic approach for
the management of BCABP and bone metastasis.
Biological actions of extracellular HMGB1 are elicited through
binding to several cell surface receptors expressed on target tissues
and cells. RAGE and TLR4 are two of the major receptors that11mediate the biological actions of HMGB1. However, functional
discrimination if RAGE and TLR4 or both are involved in many of
HMGB1’s actions in inflammation, immunity and cancer develop-
ment and progression still remains debatable. In this study, we
showed that both RAGE and TLR4 are expressed on peripherin+
SNs innervating bone and found that FPS-ZM1, a selective RAGE
antagonist, but not TAK242, a selective TLR4 antagonist, reduced
BCABP. These results suggest that RAGE rather than TLR4 mediates
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signaling pathways of RAGE following HMGB1 binding leads to
the activation of the molecular pain markers, ERK1/2 and CREB
[33]. Thus, HMGB1/RAGE/ERK1/2/CREB axis is likely a predominant
signaling pathway that leads to the induction of BCABP. Further
study will warrant to define the role of HMGB1/RAGE axis in the
regulation of neuronal reactions in response to cancer colonization
in bone.
A previous study described that HMGB1 increases RANKL-
induced osteoclastogenesis via activating RAGE, but not TRL4, sig-
naling [34]. Osteoclasts are a key player in the pathophysiology of
osteolytic bone metastasis [35]. We therefore determined if
HMGB1 derived 4T1 BC cells regulates osteolysis associated with
4T1 BC colonization in bone. Our radiological and histological anal-
yses showed decreased area of osteolytic lesions and reduced num-
ber of TRAP+ osteoclasts in tibiae of 4T1/sh HMGB1 mice compared
to 4T1 mice and 4T1/sh control mice. These results together with
an earlier report [34] indicate a crucial role of HMGB1 produced
in cancer in the development and progression of osteolytic bone
metastasis.
Our result that RANKL-induced osteoclastogenesis is enhanced
by HMGB1/RAGE axis, and accumulating data that osteoclasts con-
tribute to the induction of BCABP by releasing protons to degrade
bone minerals during bone resorption [2,28] together suggest that
reduced BCABP by administration of the neutralizing antibody to
HMGB1 and antagonists to RAGE and TLR4 to 4T1 mice is partially
due to decreased proton secretion from suppressed osteoclasts. In
fact, the specific inhibitors of osteoclasts, bisphosphonates and
denosumab, are shown to effectively improve BCABP in breast can-
cer patients [36]. However, in this study, the HMGB1 antibody and
RAGE antagonist FPS-ZM1 and TLR4 antagonist TAK-242 were
given to 4T1 mice only by one single injection and reduction of
BCABP emerged 3 h for FPS-ZM1 and 12 h for HMGB1 antibody fol-
lowing agent administration. It is thus unlikely, we suspect, that
bone resorption is inhibited within 3 to 12 h, leading to reduced
BCABP under these circumstances. Thus, HMGB1, RAGE and TLR4
play a role in the induction of BCABP via not only osteoclast-
associated mechanism but also direct activation of SNs.
In this study we found the expression of HMGB1 in human BCs
is increased compared with that in normal human breast tissue.
Further, our results also show that cytoplasmic expression of
HMGB1 is significantly greater in BCs than in normal breast tissue.
HMGB1 primarily is a structural protein of chromatin in the
nucleus that functions as a DNA chaperone, regulating nuclear
homeostasis and genome stability [10]. However, HMGB1 is
actively secreted into the extracellular environments following
translocation from the nucleus to the cytoplasm in response to
endogenous and exogenous stimuli [33]. It has been proposed that
post-translational modifications of HMGB1 by acetylation, phos-
phorylation, methylation and poly (ADP)-ribosylation promote
the translocation of HMGB1 from the nucleus to the cytoplasm,
leading to the secretion of HMGB1. Further, increased apoptosis
in cancer cells due to anti-cancer chemotherapy and radiation also
promotes HMGB1 release [10]. Although we did not investigate the
mechanism of increased cytoplasmic expression of HMGB1 in
human BC cells in this study, our results suggest that BC cells
may have the intrinsic intracellular machinery by which HMGB1
is produced in increased levels in the nucleus, translocated to the
cytoplasm, and consequently secreted into the extracellular envi-
ronments, thereby promoting the aggressiveness of BC and induc-
ing associated complications such as bone pain.
Bone is relatively hypoxic compared to other organs [37] and
hypoxia is a potent stimulator of HMGB1 secretion from cancer
cells [8], collectively suggesting that HMGB1 levels are likely up-
regulated in cancer bone metastasis. Further, bone is densely
innervated by SNs [38]. Thus, bone provides a unique microenvi-12ronment in which HMGB1 contributes to the pathophysiology of
BCABP induced via the interactions between bone metastatic can-
cer cells and SNs. Recently, HMGB1/RAGE is found to be involved in
skeletal development, homeostasis, repair and regeneration via
regulation of functions of the cellular components of bone
microenvironment including osteocytes, osteoblasts and osteo-
clasts [39]. Our results suggest that SNs are an additional compo-
nent of bone microenvironment regulated by the HMGB1/RAGE
axis, interacting with metastatic BC in the pathophysiology of
BCABP in bone microenvironment.
In conclusion, our study demonstrates that BC secretes HMGB1
to induce BCABP by activating RAGE signaling in SNs innervating
bone. We propose that HMGB1/RAGE axis may be a novel thera-
peutic target for BCABP, as well as a potential biomarker for BCABP.CRediT authorship contribution statement
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